|
Volume 5, Number 4, Supplement 2 (April 2007) | |||||
| Annual Review of Cytokines in Cancer Management | |||||
|
Summaries of selected studies of anemia, neutropenia, mucositis, and thrombocytopenia presented at four major oncology meetings in 2006, including the 42nd Annual Meeting of the American Society of Clinical Oncology, the 48th Annual Meeting of the American Society of Hematology, the 31st Annual Congress of the Oncology Nursing Society, and the 19th Annual Symposium of the Multinational Association of Supportive Care in Cancer |
|||||
|
|||||
Information About This CME/CE Activity
|
|||||
Anemia |
|||||
5 |
Anemia in Cancer: Update on Studies of Erythropoiesis-Stimulating Agents Department of Medicine, Harvard Medical School, and Breast Oncology Center, Dana-Farber Cancer Institute, Boston, Massachusetts
|
||||
SUMMARIES |
|||||
8 |
Use of darbepoetin alfa and epoetin alfa for anemia in clinical practice
|
||||
10 |
Development of the Brief Functional Capacity Tool (BFCT): a brief instrument to identify functional capacity deficits in anemic cancer patients
|
||||
12 |
Hematologic outcomes and erythropoiesis-stimulating therapy costs in epoetin alfa- and darbepoetin alfa-treated cancer patients: results of the Dosing and Outcomes Study of Erythropoiesis-stimulating therapies (DOSE) registry
|
||||
14 |
The efficacy and safety of darbepoetin alfa for treating anemia in low-risk myelodysplastic syndrome patients: results after 53/55 weeks
|
||||
16 |
Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U every two weeks) versus weekly dosing (40,000 U weekly) in anemic patients with cancer receiving chemotherapy
|
||||
18 |
The patient’s experience of fatigue: a cross-sectional study of cancer patients
|
||||
20 |
Clinical benefits and risks associated with epoetin (alfa/beta) and darbepoetin alfa in patients with chemotherapy-induced anemia: a systematic review of the literature
|
||||
22 |
A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia
|
||||
24 |
A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy
|
||||
26 |
Bibliography
|
||||
Neutropenia |
|||||
27 |
Update on Neutropenia and Myeloid Growth Factors Department of Medicine, Duke University Medical Center, and Duke Comprehensive Cancer Center, Durham, North Carolina
|
||||
SUMMARIES |
|||||
30 |
A randomized double-blind phase II study to evaluate same-day vs next-day pegfilgrastim with carboplatin and docetaxel in patients with NSCLC
|
||||
32 |
ELYPSE 2: a prospective randomized trial comparing filgrastim in primary and secondary prophylaxis in patients at high risk for febrile neutropenia
|
||||
34 |
The role of the oncology nurse in prechemotherapy neutropenic risk assessment and patient outcomes
|
||||
36 |
Final results of a large, community-based study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in non-Hodgkin’s lymphoma and Hodgkin’s lymphoma patients
|
||||
38 |
Final results of a large, community-based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy
|
||||
40 |
Pegfilgrastim provides effective primary prophylaxis against febrile neutropenia in patients with non-Hodgkin’s lymphoma undergoing chemotherapy: initial results from an integrated analysis—the Neulasta Versus Current Neutropenia Management Practice (NEUCUP) Project
|
||||
42 |
Randomized, double-blind, phase II study evaluating same-day vs
next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin’s lymphoma patients
|
||||
44 |
Economic burden of chemotherapy-related febrile neutropenia
|
||||
46 |
Bibliography
|
||||
Mucositis |
|||||
47 |
Mucositis: Continuing Progress for a Continuing Need Cardinal Bernardin Cancer Center and Division of Hematology-Oncology, Loyola University Medical Center, Maywood, Illinois
|
||||
SUMMARIES |
|||||
50 |
Prospective oral mucositis audit (POMA): occurrence and consequences of severe oral mucositis in high-dose melphalan
and BEAM conditioning
|
||||
52 |
A randomized, double-blind, placebo-controlled, multicenter trial of ATL-104, a swallowable mouthwash, in patients with oral mucositis following peripheral blood stem cell transplantation
|
||||
54 |
Oral mucositis-related morbidity and resource utilization in a prospective study of head and neck cancer patients
|
||||
56 |
The significance of palifermin in reduction of oral mucositis incidence and acute graft-versus-host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant
|
||||
58 |
Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis
|
||||
60 |
Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total-body irradiation and high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation
|
||||
62 |
Bibliography
|
||||
Thrombocytopenia |
|||||
63 |
Novel Thrombopoietic Agents: Preliminary Activity, Potential Benefit Division of Pediatric Hematology Oncology, Weill Cornell Medical College, New York, New York
|
||||
SUMMARIES |
|||||
66 |
Eltrombopag, an oral platelet growth factor, for treatment of chronic immune thrombocytopenic purpura (ITP): a randomized, double-blind, placebo-controlled trial
|
||||
68 |
Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers
|
||||
70 |
Analysis of health-related quality of life in patients receiving AMG 531 using the disease-specific Immune Thrombocytopenic Purpura Patient Assessment Questionnaire
|
||||
72 |
Rituximab is an alternative to splenectomy in adults with chronic immune thrombocytopenic purpura: results of a multicenter prospective phase II study
|
||||
74 |
The incidence and impact of thrombocytopenia in myelodysplastic syndrome
|
||||
76 |
Platelet aggregation analysis of AMG 531 in a randomized, placebo-controlled study in healthy Japanese patients
|
||||
78 |
Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update
|
||||
80 |
Bone marrow reticulin in patients with immune thrombocytopenic purpura
|
||||
82 |
Long-term follow-up of patients with immune thrombocytopenic purpura whose initial response to rituximab lasted a minimum of one year
|
||||
84 |
Bibliography
|
||||
Oncology Nursing Perspective |
|||||
85 |
A Time for Hope: Promising Advances in the Management of Anemia, Neutropenia,Thrombocytopenia, and Mucositis Arizona Cancer Center, Tucson, Arizona
|
||||
Pharmacy Perspective |
|||||
89 |
Implementation of Cytokines to Optimize Cancer Treatment Outcomes Department of Gynecology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, and Department of Obstetrics and Gynecology, University of Texas, Health Sciences Center at Houston Medical School, Houston
|
||||
Continuing Education |
|||||
93 |
CME/CE Post Test
| ||||
95 |
CME/CE Answer Sheet and Evaluation
| ||||
The EOCME, Elsevier/Mosby Office of Continuing Nursing Education, and Elsevier Oncology gratefully acknowledge the educational grant provided by Amgen, Inc. |
|||||
© 2007 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the publisher. |
|||||
174 kb